SCHOLAR ROCK HOLDING CORPORATION Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
SCHOLAR ROCK HOLDING CORPORATION (SRRK) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $1.30 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-06
- SCHOLAR ROCK HOLDING CORPORATION right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-06-30 was $0.00.
- SCHOLAR ROCK HOLDING CORPORATION right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-03-31 was $1.30M.
- SCHOLAR ROCK HOLDING CORPORATION right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-12-31 was $0.00.
- SCHOLAR ROCK HOLDING CORPORATION right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-12-31 was $0.00.
- SCHOLAR ROCK HOLDING CORPORATION right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $31.29M, a 474.69% increase from fiscal 2019.
- SCHOLAR ROCK HOLDING CORPORATION right-of-use asset obtained in exchange for operating lease liability for fiscal 2019 was $5.44M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.30M 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | $1.30M 10-Q · filed 2026-05-07 | |||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-06 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $31.29M 10-K · filed 2022-03-07 | ||
| 2020-09-30 | $31.29M 10-Q · filed 2021-11-09 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $95.00K derived: sum of 2 quarters · filed 2021-03-09 | $95.00K derived: sum of 3 quarters · filed 2021-03-09 | $5.44M 10-K · filed 2021-03-09 |
| 2019-09-30 | $95.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $95.00K derived: sum of 2 quarters · filed 2020-11-09 | $5.44M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $5.35M 10-Q · filed 2020-08-07 | ||
| 2019-03-31 | $5.35M 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |